Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

Información selecta para pacientes y cuidadores que se encuentra disponible en Español.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

HEXTEND (6% Hetastarch in Lactated Electrolyte Injection)

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

HEXTEND Quick Finder

WARNING: MORTALITY; KIDNEY INJURY; COAGULOPATHY

  • Use of hydroxyethyl starch (HES) products, including HEXTEND, increases risk of
    • Mortality
    • Kidney...
Did you find an answer to your question? Yes No

INDICATIONS AND USAGE

HEXTEND (6% Hetastarch in Lactated Electrolyte Injection) is indicated in the treatment of hypovolemia when plasma volume expansion is desired in settings where adequate alternative treatment is...

Did you find an answer to your question? Yes No

DOSAGE AND ADMINISTRATION

Dosage for Acute Use in Plasma Volume Expansion

HEXTEND is administered by intravenous infusion only. Total dosage and rate of infusion...

Did you find an answer to your question? Yes No

CONTRAINDICATIONS

Do not use HES products, including HEXTEND, unless adequate alternative treatment is unavailable.

Did you find an answer to your question? Yes No

WARNINGS AND PRECAUTIONS

  • Increased risk of mortality and acute kidney injury (AKI) in critically ill patients, including patients with sepsis; surgical patients; and blunt trauma patients
  • Avoid use in patients...
Did you find an answer to your question? Yes No

ADVERSE REACTIONS

Serious adverse reactions reported in postmarketing clinical trials include increased mortality and AKI (including need for RRT) in critically ill subjects, including subjects with sepsis, and surgical...

Did you find an answer to your question? Yes No

HEXTEND® (6% Hetastarch in Lactated Electrolyte Injection) is a sterile, nonpyrogenic solution for intravenous administration. The composition, pH, and osmolarity are given in

...
Did you find an answer to your question? Yes No

CLINICAL PHARMACOLOGY

The plasma volume expansion produced by HEXTEND approximates that produced by 6% Hetastarch in 0.9% Sodium Chloride Injection and the plasma volume expansion of 6% Hetastarch in 0.9% Sodium Chloride...

Did you find an answer to your question? Yes No

CLINICAL STUDIES

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another...

Did you find an answer to your question? Yes No

HOW SUPPLIED

HEXTEND (6% Hetastarch in Lactated Electrolyte Injection) is supplied sterile and nonpyrogenic in 500 mL single-dose flexible plastic infusion containers.

...
Did you find an answer to your question? Yes No

6% Hetastarch in Lactated Electrolyte Injection

Flexible Plastic Container

Did you find an answer to your question? Yes No
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event